Chemed Corp (CHE) Drops 5.07% on February 18

Equities Staff |

Chemed Corp (CHE) was one of the Russell 2000's biggest losers for Thursday February 18 as the stock slid 5.07% to $128.16, a loss of $-6.84 per share. Starting at an opening price of $132.58 a share, the stock traded between $127.76 and $134.14 over the course of the trading day. Volume was 161,961 shares over 1,816 trades, against an average daily volume of 142,183 shares and a total float of 16.88 million.

The losses send Chemed Corp down to a market cap of $2.16 billion. In the last year, Chemed Corp has traded between $160.12 and $110.53, and its 50-day SMA is currently $143.77 and 200-day SMA is $139.05.

The stock has a P/E Ratio of 21.4.

Chemed Corp through its subsidiaries, operates in the healthcare and plumbing business in the United States. The Company's business segments include VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter).

Chemed Corp is based out of Cincinnati, OH and has some 14,190 employees. Its CEO is Kevin J. Mcnamara.

For a complete fundamental analysis analysis of Chemed Corp, check out’s Stock Valuation Analysis report for CHE. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…